You can't always get what you want, but if you try sometimes (with two tests—TST and IGRA—for tuberculosis) you get what you need
Open Access
- 1 November 2012
- journal article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 71 (11) , 1757-1760
Abstract
TB is rumoured to infect nearly a third of the world's population. The risk of LTBI progression to active TB is clearly heightened by antitumour necrosis factor α (anti-TNF) therapy, and the absolute risk of this complication is driven by the background prevalence of LTBI in a particular region and the probability of infection in an individual. Within low prevalence countries, rates of anti-TNF-associated TB are typically 5–10-fold higher than background general populations, with greater relative risks reported from countries of higher TB prevalence.5–8 Screening for LTBI with the TST prior to anti-TNF start has been associated with decreasing anti-TNF-associated TB incidence, and in the past several years, data suggest that algorithms using IGRAs can assist in identifying infected patients prior to initiation of therapy.1 , 9–12 These tests incorporate antigens with high specificity for TB that most importantly do not cross react with Mycobacterium bovis strains used in BCG vaccine, and they do no cross react with most clinically relevant non-tuberculous mycobacteria (although with several notable exceptions such as Mycobacterium marinum, Mycobacterium kansasii and Mycobacterium szulgai). Accordingly, these tests are of greater specificity for TB, and in populations where BCG has been used, they categorise more accurately which patients are infected.13 Ideally, any optimal screening strategy maximises the number of truly infected persons identified and minimises the number of patients falsely diagnosed with LTBI. However, in immunosuppressive or other high risk settings, we have traditionally (and understandably) favoured sensitivity in screening for LTBI.Keywords
This publication has 23 references indexed in Scilit:
- Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assayAnnals of the Rheumatic Diseases, 2012
- Comparison of Two Gamma Interferon Release Assays and Tuberculin Skin Testing for Tuberculosis Screening in a Cohort of Patients with Rheumatic Diseases Starting Anti-Tumor Necrosis Factor TherapyClinical and Vaccine Immunology, 2011
- The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statementEuropean Respiratory Journal, 2010
- Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics RegisterAnnals of the Rheumatic Diseases, 2010
- Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registryArthritis & Rheumatism, 2009
- QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseasesEuropean Respiratory Journal, 2008
- Screening for tuberculosis infection prior to initiation of anti-TNF therapyAutoimmunity Reviews, 2008
- Interferon-γ Release Assays for Diagnosing Mycobacterium tuberculosis Infection in Renal Dialysis PatientsClinical Journal of the American Society of Nephrology, 2008
- Tuberculosis associated with therapy against tumor necrosis factor αArthritis & Rheumatism, 2005
- Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonistsArthritis & Rheumatism, 2005